Abstract
Alzheimers disease (AD) is the leading cause of dementia. Although the etiology of AD remains controversial, the amyloid hypothesis suggests that β-amyloid (Aβ) peptides may contribute to brain dysfunction, and microglial activation has become increasingly regarded as a potential contributor to disease pathogenesis. Microglial activation is characterized by morphological changes and by production of various effectors, and activated neuroinflammation concurrent with increased oxidative stress may contribute to damage to neurons. However, recently there has been a recognition that microglia may also play a neuroprotective role through their release of neurotrophic factors and through phagocytosis of Aβ. Thus, there is growing consensus that a favorable combination of diminished microglia- mediated neuroinflammation and enhanced Aβ clearance may be critical in AD therapy. In this review, we will discuss the role of microglial activation in AD and how pharmacologic manipulation of microglia might bear upon the treatment of AD.
Keywords: Alzheimer's disease, microglial activation, neuroinflammation, beta-amyloid, tau, therapy
Current Medicinal Chemistry
Title: Manipulation of Microglial Activation as a Therapeutic Strategy in Alzheimers Disease
Volume: 14 Issue: 27
Author(s): Feng-Shiun Shie and Randall L. Woltjer
Affiliation:
Keywords: Alzheimer's disease, microglial activation, neuroinflammation, beta-amyloid, tau, therapy
Abstract: Alzheimers disease (AD) is the leading cause of dementia. Although the etiology of AD remains controversial, the amyloid hypothesis suggests that β-amyloid (Aβ) peptides may contribute to brain dysfunction, and microglial activation has become increasingly regarded as a potential contributor to disease pathogenesis. Microglial activation is characterized by morphological changes and by production of various effectors, and activated neuroinflammation concurrent with increased oxidative stress may contribute to damage to neurons. However, recently there has been a recognition that microglia may also play a neuroprotective role through their release of neurotrophic factors and through phagocytosis of Aβ. Thus, there is growing consensus that a favorable combination of diminished microglia- mediated neuroinflammation and enhanced Aβ clearance may be critical in AD therapy. In this review, we will discuss the role of microglial activation in AD and how pharmacologic manipulation of microglia might bear upon the treatment of AD.
Export Options
About this article
Cite this article as:
Shie Feng-Shiun and Woltjer L. Randall, Manipulation of Microglial Activation as a Therapeutic Strategy in Alzheimers Disease, Current Medicinal Chemistry 2007; 14 (27) . https://dx.doi.org/10.2174/092986707782359981
DOI https://dx.doi.org/10.2174/092986707782359981 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Does the Cholinesterase Inhibitor, Donepezil, Benefit Both Declarative and Non-Declarative Processes in Mild to Moderate Alzheimers Disease?
Current Alzheimer Research Glycogen Synthase Kinase-3: A Potential Target for Drug Discovery in the Treatment of Neurodegenerative Disorders
Current Enzyme Inhibition Neonatal Atlas Templates for the Study of Brain Development Using Magnetic Resonance Images
Current Medical Imaging Editorial [“Current Aging Science”: An Important Platform for Reporting Advances in Aging-related Research]
Current Aging Science Commentary Research Highlights (Amyloid and Alzheimer's Disease: Easing the Load)
CNS & Neurological Disorders - Drug Targets Cognitive Training in Patients with Alzheimer's Disease: Findings of a 12-month Randomized Controlled Trial
Current Alzheimer Research Mitophagy in Neurodegeneration: An Opportunity for Therapy?
Current Drug Targets Targeting of α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia and the Use of Auditory Sensory Gating as a Translational Biomarker
Current Pharmaceutical Design Design and Synthesis of Dopaminergic Agonists
Current Medicinal Chemistry Dual Inhibitors of Monoamine Oxidase and Cholinesterase for the Treatment of Alzheimer Disease
Current Topics in Medicinal Chemistry Converging Pathways in the Occurrence of Endoplasmic Reticulum (ER) Stress in Huntingtons Disease
Current Molecular Medicine Enriched Environment Prevents Cognitive Impairment and Tau hyperphosphorylation after Chronic Cerebral Hypoperfusion
Current Neurovascular Research Trigonelline: A Plant Alkaloid with Therapeutic Potential for Diabetes and Central Nervous System Disease
Current Medicinal Chemistry Post-Translational Protein Modifications of Rare and Unconventional Types: Implications in Functions and Diseases
Current Medicinal Chemistry Excitotoxicity as a Target Against Neurodegenerative Processes
Current Pharmaceutical Design The Science of Hypoglycemia in Patients with Diabetes
Current Diabetes Reviews Is Atorvastatin Superior to Other Statins? Analysis of the Clinical Trials with Atorvastatin Having Cardiovascular Endpoints
Reviews on Recent Clinical Trials New Therapeutic Strategies for Cancer and Neurodegeneration Emerging from Yeast Cell-based Systems
Current Pharmaceutical Design Cholesterol and Apoe: A Target for Alzheimers Disease Therapeutics
Current Drug Targets - CNS & Neurological Disorders Vpu: A Multifunctional Protein that Enhances the Pathogenesis of Human Immunodeficiency Virus Type 1
Current HIV Research